This is an archive of the Treatment Action Campaign's public documents from
December 1998 until October 2008. I created this website because the TAC's
website appears unmaintained and people were concerned that it
was becoming
increasingly hard to find important documents.
The menu items have
been slightly edited and a new stylesheet applied to the site. But none of the
documents have been edited, not even for minor errors. The text appears on this
site as obtained from the Internet Archive.
The period covered by
the archive encompassed the campaign for HIV medicines, the civil disobedience
campaigns, the Competition Commission complaints, the 2008 xenophobic violence
and the PMTCT, Khayelitsha health workers and Matthias Rath court cases.
5 March 2007
The Treatment Action Campaign (TAC) will hold imbizos in six provinces to discuss the contents of the draft National Strategic Plan for HIV/AIDS and Sexually Transmitted Infections (NSP) and inform the final document. Space is limited to 150 people per meeting. The HSRC is kindly assisting us with the content of the meetings. Please contact the provincial TAC office in your area if your organisation wishes to send a delegate.
Gauteng (Tel. 011 339 8421):
Ekhuruleni: Natalspruit Hospital, 6 March, 10am
Mpumalanga (Tel. 013 755 2298)
Secunda: Casper Breed Centre (next to Secunda Stadium), 6 March, 10am
Western Cape (Tel. 021 447 2593):
Atlantis: Hartebees Multipurpose Centre, 7 March, 11am
Khayelitsha (date and venue to be confirmed)
Eastern Cape (Tel. 043 722 2645):
Lusikisiki" Qawukeni Great Place, 7 March, 10am
Limpopo (Tel. 015 291 5448):
Giyani: Oasis Lodge, 8 March, 10am
KZN (Tel. 031 304 3673):
Pietermaritzburg: African Enterprise, 9 March, 10am
For media comment, please call TAC National Organiser Linda Mafu on 021 788 3507 or 084 300 7037.
The agenda for each Imbizo is as follows:
Overview of the NSP
Small Group discussions on the following: Each will be preceded by a lead in discussion.
Prevention
Treatment, Care & Support
Human and Legal Rights
TB
Gender and HIV
Plenary
Summary
[END OF NEWSLETTER]